Gamco Investors INC. ET AL Takes Position in Niagen Bioscience, Inc. $NAGE

Gamco Investors INC. ET AL acquired a new position in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 125,450 shares of the company’s stock, valued at approximately $1,170,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Financial Consulate Inc. bought a new stake in Niagen Bioscience in the 3rd quarter valued at $33,000. State of Alaska Department of Revenue bought a new position in shares of Niagen Bioscience during the third quarter worth approximately $44,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Niagen Bioscience in the third quarter valued at approximately $45,000. North Star Investment Management Corp. bought a new stake in shares of Niagen Bioscience in the third quarter valued at approximately $47,000. Finally, Quantbot Technologies LP bought a new stake in shares of Niagen Bioscience in the third quarter valued at approximately $48,000. 15.41% of the stock is currently owned by institutional investors and hedge funds.

Niagen Bioscience Trading Up 2.2%

Shares of Niagen Bioscience stock opened at $5.22 on Wednesday. The company has a market cap of $418.02 million, a PE ratio of 26.10 and a beta of 2.11. The company has a 50 day moving average of $5.69 and a 200-day moving average of $7.04. Niagen Bioscience, Inc. has a 1-year low of $4.72 and a 1-year high of $14.69.

Analyst Ratings Changes

A number of brokerages recently issued reports on NAGE. Canaccord Genuity Group reduced their price target on Niagen Bioscience from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered Niagen Bioscience from a “buy” rating to a “hold” rating in a report on Saturday. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Niagen Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Niagen Bioscience Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.